Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer
Authors
Keywords
-
Journal
PLoS One
Volume 7, Issue 2, Pages e30269
Publisher
Public Library of Science (PLoS)
Online
2012-02-14
DOI
10.1371/journal.pone.0030269
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.
- (2017) R. A. Burger et al. JOURNAL OF CLINICAL ONCOLOGY
- OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).
- (2017) C. Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor κB Pathway and Is Associated with Poor Overall Survival
- (2015) Adam Clauss et al. NEOPLASIA
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets
- (2010) Kosuke Yoshihara et al. PLoS One
- A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2
- (2009) Samuel C. Mok et al. CANCER CELL
- Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma
- (2009) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- A prognostic gene expression index in ovarian cancer-validation across different independent data sets
- (2009) Carsten Denkert et al. JOURNAL OF PATHOLOGY
- GeneSigDB—a curated database of gene expression signatures
- (2009) Aedín C. Culhane et al. NUCLEIC ACIDS RESEARCH
- Whole-Genome Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissue Samples
- (2009) Craig April et al. PLoS One
- Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer
- (2009) Anne P. G Crijns et al. PLOS MEDICINE
- lumi: a pipeline for processing Illumina microarray
- (2008) P. Du et al. BIOINFORMATICS
- A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
- (2008) T. Bonome et al. CANCER RESEARCH
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
- Model-based variance-stabilizing transformation for Illumina microarray data
- (2008) Simon M. Lin et al. NUCLEIC ACIDS RESEARCH
- Highly sensitive and specific microRNA expression profiling using BeadArray technology
- (2008) Jing Chen et al. NUCLEIC ACIDS RESEARCH
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
- (2008) L. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started